Jefferies Global Healthcare Conference in London - LIQUIDIA CORP
Explicit Guidance:
- Revenue & Growth: Expect October 2026 to be the "most disruptive month" of the launch with referral rates at 75% of Q3 daily levels; anticipate sequential growth for the remainder of 2026, 2027, and beyond.
- Margins: Target >50% operating margins in 2027; SG&A expenses as a percentage of sales expected to decline quarter-on-quarter, while R&D costs are planned to increase quarter-on-quarter.
- Cash & Capex: Ended Q3 with ~$400M cash; net settlement payments to United Therapeutics totaling ~$380M through April 2027; no ongoing royalties or payments post-April 2027.
- Clinical Timeline: Plan to have 10 clinical trials operational by late 2026 (including three registrational studies); aim to initiate the "Amplify PAH" pivotal trial in 2027; target enrollment completion in 2028, data readout in 2029, and NDA filing thereafter.
Business-Segment Outlook:
- Eutrepia (PAH): Targeting the full ~$4B prostacyclin market; currently hold >30% market share (as of Sept 2026) in an entrenched market; primary focus on expanding share across oral, inhaled, and parenteral patient pools.
- Eutrepia (PHILD): Existing patients on Eutrepia for PHILD will not be required to switch; no significant formulary changes or payer pressure anticipated to force alternative therapies during 2027 reauthorizations.
- Eutrepia (Expansion): Initiating Phase IV studies in 2026/2027 to validate transitions from oral to inhaled therapies and demonstrate a 3-times-daily dosing regimen; launching the "EZPH" registry in 2027 to capture real-world evidence on dosing flexibility.
- L606 (Pipeline): Priority indication is PHCOPD (300k+ patient population); also targeting systemic sclerosis with Raynaud's phenomenon (Phase 2 dose-finding expected Q1 2027); secondary interest in IPF/PPF via high-dose studies.
- Product Portfolio Strategy: Positioning L606 (nebulized, twice-daily) as the preferred entry point for new PAH patients due to consistent peak-to-trough exposure; expect potential case-by-case transitions from Eutrepia to L606 for existing patients; Eutrepia to focus on PHILD and potentially Raynaud's.
Market and Competitive Outlook:
- Competitive Landscape: Liquidia views the settlement as removing the legal overhang, allowing a pure "growth story" focus; anticipates continued market share gains against competitors in an entrenched market.
- Differentiation: Leveraging Eutrepia's superior titration flexibility and lower dosing frequency (3x vs. 5x) as key differentiators against oral prostacyclins; L606 positioned to offer twice-daily sustained exposure vs. current inhaled competitors.
- Switching Dynamics: Active pursuit of switching opportunities from oral and parenteral prostacyclins to inhaled therapy based on tolerability profiles and "local delivery" benefits.
Macro / Industry Outlook:
- Regulatory Environment: Confident in the 505(b)(1) pathway for L606 despite the inability to reference Tyvaso (requiring separate PAH and PHILD trials); believes the regulatory risk for the 2029 readouts is manageable.
- Litigation Risk: Confident in Freedom to Operate for L606 due to distinct device mechanics (nebulized dose vs. breath-actuated) compared to the expired/limited '327 patent; company is prepared for potential future litigation but prioritizes "patience."
- Economic/Capital Climate: No macro headwinds cited; confidence in generating significant free cash flow in 2027 to fund internal pipeline and potential external M&A/partnerships post-settlement.
Strategic Initiatives:
- Clinical Expansion: 10 trials planned by late 2026 (3 registrational); specific focus on Phase 3 pivotal studies for L606 in PHCOPD and systemic sclerosis.
- Commercial Execution: Launching a "show me" strategy to prove growth post-settlement; maintaining a "laser-focused" sales force for PHILD and PAH transitions.
- M&A/External Opportunities: Evaluating external partnerships or acquisitions if they align with patient benefit and shareholder value, particularly in clinical or commercial opportunities.
- Real-World Evidence: Initiating Phase IV open-label studies to generate data on oral-to-inhaled transitions and safety algorithms for dose titration.
Risks and Headwinds to Outlook:
- Clinical Failure: Outcome of Phase 2 dose-finding study for systemic sclerosis (Q1 2027) dictates progression to Phase 3; success dependent on achieving a viable dose for symptomatic improvement.
- Regulatory Execution: Need to complete two separate pivotal trials (PAH and PHILD) for L606 to secure approval, as the 505(b)(2) path referencing Tyvaso is no longer available.
- Adoption Barriers: Potential challenges in transitioning existing patients from Eutrepia to L606, though viewed as a long-term, case-by-case strategy.
- Settlement Timing: Cash flow impact of ~$380M settlement payments through April 2027, though no further payments expected thereafter.
Management Tone on the Future:
- Confidence Level: Highly confident and optimistic; management describes the post-settlement environment as a "great time" for the company with no remaining legal overhang.
- Execution Focus: Emphasizes a "show me" approach, relying on execution to drive growth rather than litigation outcomes.
- Long-Term Vision: Clear view of L606 as the "dominant force" in the long term, with Eutrepia maintaining a role in specific indications (PHILD, Raynaud's); sentiment indicates strong belief in the company's ability to create "tremendous value for shareholders."
Miscellaneous:
- Device Technology: L606 utilizes a "next-generation breath-actuated nebulizer" delivering the full loading dose, distinct from breath-actuated competitors like Tyvaso which dose per breath.
- Patient Benefits: Emphasis on "patient benefit" as the core driver for all strategic decisions, including clinical trial design and commercial focus.
- Company
- LIQUIDIA CORP
- Keywords
- LIQUIDIA CORP